MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference
22 5월 2023 - 9:30PM
MiNK Therapeutics (Nasdaq: INKT), a clinical-stage
biopharmaceutical company specializing in the discovery,
development, and commercialization of allogeneic, off-the-shelf,
invariant natural killer T (iNKT) cell therapies to treat cancer
and other immune-mediated diseases, today announced presentation of
clinical data from its allo-iNKTs (agenT-797) in COVID-19
associated Acute Respiratory Distress Syndrome (CARDS) at the
American Thoracic Society (ATS) International Conference in
Washington D.C.
“The encouraging activity, tolerability, and ease of
administration seen with allogeneic iNKT cells in patients with
CARDS suggests the important role that cellular based therapies
could play in infectious, inflammatory diseases, and autoimmunity,”
said Dr. Terese C. Hammond, Medical Director, Providence Saint
John’s Health Center and Sound Physicians. “Addressing immune
system dysfunction is essential to improving outcomes in critical
illness. I believe these results illuminate how novel immune cell
interventions can have an impactful role in treating in acute
critical illness.”
Twenty patients with moderate to severe CARDS, including 4
patients on venovenous extracorporeal membrane oxygenation (VV
ECMO) therapy, were treated with a single dose of agenT-797.
Clinical results showed pronounced survival benefit and manageable
safety profile including:
- Patients on VV ECMO treated with
agenT-797 had 75% 90-day survival compared to 30% survival with
in-hospital controls.
- agenT-797 was dosed to 1 billion
cells with a tolerable safety profile, without oxygenation failure
or other significant adverse events, including cytokine release
syndrome (CRS).
- agenT-797 induced significant
anti-inflammatory profile changes and improved lung function
(radiologic) within 24 hours after administration in a patient on
VV ECMO support.
- In the overall study, agenT-797
showed reduction in secondary infections, including an over 80%
reduction in pneumonia at dose cohort 3 (1 X 10^9 cells). Bacterial
pneumonia in one patient on VV ECMO cleared 12 days post-infusion
of agenT-797.
The full poster presentation can be found on the Publications
Page of the MiNK website at
https://minktherapeutics.com/publications/.
Forward Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding the therapeutic and
curative potential of agenT-797 and iNKT cells the mechanism of
action, potency and safety, interim or top-line data, including
statements regarding clinical data of agenT-797, the anticipated
benefits of agenT-797 and clinical development plans and timelines.
These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These forward-looking statements are subject to risks and
uncertainties, including the factors described under the Risk
Factors section of the most recent Form 10-K, Form 10-Q and the S-1
Registration Statement filed with the SEC. MiNK cautions investors
not to place considerable reliance on the forward-looking
statements contained in this release. These statements speak only
as of the date of this press release, and MiNK undertakes no
obligation to update or revise the statements, other than to the
extent required by law. All forward-looking statements are
expressly qualified in their entirety by this cautionary
statement.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery, development, and commercialization of
allogeneic invariant natural killer T (iNKT) cell therapies to
treat cancer and other immune-mediated diseases. MiNK is advancing
a pipeline of both native and next generation engineered iNKT
programs, with a platform designed to facilitate scalable and
reproducible manufacturing for off-the-shelf delivery. The company
is headquartered in New York, NY. For more information, visit
https://minktherapeutics.com/. Follow us on Twitter @MiNK_iNKT.
Contact
Alexa Buffa781-674-4428communications@minktherapeutics.com
Investor relations: Zack
Armen917-362-1370investor@minktherapeutics.com
MiNK Therapeutics (NASDAQ:INKT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
MiNK Therapeutics (NASDAQ:INKT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024